Asthma timed drug administration

The timing of drug administration can be individualized. If the patient has combined asthma and seasonal allergic rhinitis, the dose should be given in the evening. 

In the United States, use of CFC propellants, designated as Propellants 11, 12, and 114, is strictly limited to specialized medicinal aerosol products such as MDIs for asthma. Most of the countries of the world (except Third World countries) have also banned the use of CFC s for aU aerosols except pharmaceutical and medicinal use. The U.S. Food and Drug Administration (FDA) does not intend to prohibit the use of these CFCs in the exempted MDIs until such time as a sufficient number of alternative inhalers become available and their use has been accepted by both patient and physician. 

Proving effective reversed targeting, which results from the soft nature of this steroid, systemic levels or effects cannot be detected even after chronic ocular administration [57], Plasma levels of loteprednol etabonate and its primary metabolite (PJ-91) were less than the 1 ng/L detection limit in 10 healthy volunteers who received the drug in both eyes eight times daily for 2 days and four times daily for a further 41 days [57], In addition to its already approved uses, loteprednol etabonate is also being developed for the treatment of colitis, atopic dermatitis, and asthma based on promising results from animal studies [47, 48],... 

---